Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein -Catenin, The SAPHIRE Trial

• Status: RECRUITING
• Trial end date: 2027-08-31

Summary

This phase I/II trial studies the side effects and best dose of sapanisertib when given together with cabozantinib, and to see how well they work in treating patients with liver cancer that has spread from where it first started to other places in the body (metastatic) and contains a mutation (change) in the -catenin gene. Sapanisertib and cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving sapanisertib and cabozantinib together may work better than giving cabozantinib alone in treating -catenin-mutated metastatic hepatocellular carcinoma.

• Phase: PHASE1

Details

• Lead Sponsor: National Cancer Institute (NCI)
• Treatments: cabozantinib; sapanisertib; Specimen Handling; X-Rays